M. Martín Jiménez

Incidence of venous thromboembolism (VTE) in ambulatory pancreatic cancer patients receiving chemotherapy and analysis of Khorana’s predictive model

A. M. Muñoz Martín, A. B. Rupérez Blanco, P. García Alfonso, 2014, Clinical and Translational Oncology.

Spanish Society of Medical Oncology consensus on the use of erythropoietic stimulating agents in anaemic cancer patients

R. Colomer, M. González Barón, C. Camps Herrero, 2009, Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico.

Clinical guide SEOM on venous thromboembolism in cancer patients

A. M. Muñoz Martín, M. Martín Jiménez, P. Borrega, 2014, Clinical and Translational Oncology.

Incidence of venous thromboembolism in patients with colorectal cancer according to oncogenic status

A. M. Muñoz Martín, P. García Alfonso, M. Martín Jiménez, 2020, Clinical and Translational Oncology.

Outpatient management of incidental pulmonary embolism in cancer patient

A. M. Muñoz Martín, M. Martín Jiménez, Á. García Pérez, 2019, Clinical and Translational Oncology.

New remains from the Spanish Cenomanian shed light on the Gondwanan origin of European Early Cretaceous titanosaurs

A. Pérez‐García, F. Ortega, P. Mocho, 2019, Cretaceous Research.

LBA4 Updated overall survival (OS) results from the first-line (1L) population in the phase III MONALEESA-3 trial of postmenopausal patients (PTS) with HR+/HER2− advanced breast cancer (ABC) treated with ribociclib (RIB) + fulvestrant (FUL)

P. Fasching, P. Neven, C. Wang, 2022, Annals of Oncology.

Systematic study of the historical material of Upper Cretaceous reptiles from the Tremp Basin (Catalonia, Spain) housed at the Museo Nacional de Ciencias Naturales (Madrid)

A. Pérez‐García, F. Ortega, P. Mocho, 2017, Journal of Iberian Geology.

162O Primary analysis from DS8201-A-U105: A 2-part, open label, phase Ib trial assessing trastuzumab deruxtecan (T-DXd) with nivolumab (nivo) in patients (pts) with HER2-expressing advanced breast cancer

C. Shapiro, P. Debruyne, S. Hurvitz, 2022, Annals of Oncology.

211MO Giredestrant (GDC-9545) vs physician choice of endocrine monotherapy (PCET) in patients (pts) with ER+, HER2– locally advanced/metastatic breast cancer (LA/mBC): Primary analysis of the phase II, randomised, open-label acelERA BC study

A. Bardia, A. Montero, J. Martinalbo, 2022, Annals of Oncology.

60MO Ovarian function in young patients (pts) treated with postneoadjuvant palbociclib (PAL) and endocrine therapy (ET) for hormone receptor (HR)-positive, HER2-negative early breast cancer (BC): Explorative analysis in Penelope-B

C. Denkert, F. Marmé, V. Nekljudova, 2022, Annals of Oncology.

New clinical trials regulation in Spain: analysis of royal decree 1090/2015

R. García-Campelo, E. González-Flores, M. Martín Jiménez, 2016, Clinical and Translational Oncology.

LBA17 Adjuvant abemaciclib plus endocrine therapy for HR+, HER2-, high-risk early breast cancer: Results from a preplanned monarchE overall survival interim analysis, including 5-year efficacy outcomes

B. San Antonio, A. Shahir, M. Martín Jiménez, 2023, Annals of Oncology.

Incidence of venous thromboembolism in patients with colorectal cancer according to oncogenic status

A. M. Muñoz Martín, P. García Alfonso, M. Martín Jiménez, 2020, Clinical and Translational Oncology.